Compare ALEX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALEX | NTLA |
|---|---|---|
| Founded | 1870 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2016 |
| Metric | ALEX | NTLA |
|---|---|---|
| Price | $20.78 | $11.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 18 |
| Target Price | ★ $21.00 | $18.34 |
| AVG Volume (30 Days) | 671.0K | ★ 5.9M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.74% | N/A |
| EPS Growth | ★ 65.09 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $226,062,000.00 | $57,528,000.00 |
| Revenue This Year | N/A | $1.71 |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $20.53 | ★ N/A |
| Revenue Growth | N/A | ★ 33.52 |
| 52 Week Low | $15.07 | $5.90 |
| 52 Week High | $21.03 | $28.25 |
| Indicator | ALEX | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 47.64 |
| Support Level | $20.73 | $11.21 |
| Resistance Level | $20.77 | $12.54 |
| Average True Range (ATR) | 0.04 | 1.09 |
| MACD | -0.06 | -0.29 |
| Stochastic Oscillator | 72.73 | 15.19 |
Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.